Nakamoto S, Watanabe J, Ohtani S, Morita S, et al. Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study. BMC Cancer 2022;22:31.
PMID: 34980019